Gilead Sciences’ (GILD) “Hold” Rating Reiterated at BMO Capital Markets

Gilead Sciences (NASDAQ:GILD)‘s stock had its “hold” rating reaffirmed by stock analysts at BMO Capital Markets in a research note issued to investors on Wednesday, January 3rd.

GILD has been the subject of a number of other reports. Berenberg Bank set a $96.00 price objective on shares of Gilead Sciences and gave the stock a “buy” rating in a research note on Thursday, October 19th. Royal Bank of Canada began coverage on shares of Gilead Sciences in a research note on Thursday, September 14th. They set an “outperform” rating and a $94.00 target price for the company. JPMorgan Chase & Co. set a $85.00 target price on shares of Gilead Sciences and gave the company a “buy” rating in a research note on Wednesday, October 25th. Credit Suisse Group reaffirmed a “buy” rating and set a $82.00 target price on shares of Gilead Sciences in a research note on Thursday, December 7th. Finally, Zacks Investment Research cut shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Wednesday, December 27th. Two analysts have rated the stock with a sell rating, thirteen have issued a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $85.03.

Gilead Sciences (GILD) traded down $0.04 on Wednesday, reaching $79.02. 6,341,748 shares of the company’s stock traded hands, compared to its average volume of 8,150,000. The company has a quick ratio of 3.56, a current ratio of 3.68 and a debt-to-equity ratio of 1.10. Gilead Sciences has a fifty-two week low of $63.76 and a fifty-two week high of $86.27. The company has a market capitalization of $103,190.00, a P/E ratio of 8.99, a PEG ratio of -1.58 and a beta of 1.13.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.13 by $0.14. The firm had revenue of $6.51 billion during the quarter, compared to analysts’ expectations of $6.40 billion. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The company’s revenue for the quarter was down 13.2% compared to the same quarter last year. During the same period in the prior year, the company posted $2.75 earnings per share. research analysts expect that Gilead Sciences will post 8.53 earnings per share for the current year.

In other news, insider John F. Milligan sold 220,000 shares of the business’s stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $72.88, for a total value of $16,033,600.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Gregg H. Alton sold 15,000 shares of the business’s stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $74.82, for a total transaction of $1,122,300.00. Following the completion of the sale, the executive vice president now owns 77,363 shares of the company’s stock, valued at approximately $5,788,299.66. The disclosure for this sale can be found here. Insiders have sold a total of 461,666 shares of company stock valued at $34,072,567 in the last quarter. 1.30% of the stock is currently owned by company insiders.

Several institutional investors have recently modified their holdings of the company. Welch Investments LLC purchased a new stake in Gilead Sciences during the 3rd quarter worth approximately $108,000. Wealthcare Advisory Partners LLC purchased a new stake in Gilead Sciences during the 3rd quarter worth approximately $133,000. Horan Capital Advisors LLC. purchased a new stake in Gilead Sciences during the 3rd quarter worth approximately $144,000. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in Gilead Sciences during the 2nd quarter worth approximately $147,000. Finally, Hanson & Doremus Investment Management grew its position in Gilead Sciences by 806.5% during the 3rd quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock worth $147,000 after purchasing an additional 1,613 shares during the last quarter. 75.94% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “Gilead Sciences’ (GILD) “Hold” Rating Reiterated at BMO Capital Markets” was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this article on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this article can be viewed at https://ledgergazette.com/2018/01/12/bmo-capital-markets-reiterates-hold-rating-for-gilead-sciences-gild.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply